, Volume 13, Issue 4, pp 206-214

What are cancer patients’ preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Goals of the work

In order to strengthen cancer patients’ autonomy and to improve quality of palliative care, it is necessary to know what are the patients’ preferences for treatment at the end of life, whether they accept the idea of advance directives, and who should initiate the process of fulfilling such a document.

Patients and methods

We compared cancer patients’ preferences with respect to particular treatment options at the end of life, acceptance of the idea of advance directives, and preferences for whom should initiate writing such a document with that of healthy controls, nursing staff, and physicians (n=100 each group) using a structured questionnaire.

Results

Cancer patients wanted treatment with antibiotics and infringing treatments such as chemotherapy and dialysis significantly more often than healthy controls, nursing staff, and physicians (p<0.01 and p<0.001, respectively). Determinants associated with the wish to opt for these treatments were reduced health condition and older age. The groups did not differ with respect to their acceptance of advance directives; 58–75% of all those surveyed wanted their physicians to initiate a discussion about writing such a document if they thought it appropriate.

Conclusions

Cancer patients’ preferences for treatment at the end of life significantly differ compared to other groups. Oncologists should initiate a discussion about an advance directive when/if the course of the illness seems to make this appropriate, which corresponds to the wish of the majority of cancer patients, healthy controls, and medical staff.

Parts of this work were presented during the 26th German Cancer Conference, Berlin, Germany, 27 February–1 March 2004.
This paper contains work of the doctoral thesis of one of the authors (WR) submitted to the faculty of medicine at the Johannes-Gutenberg-University, Mainz, Germany.
Competing interest statement: The authors declare no competing interests.
Ethics approval: The study was approved by the ethics committee of the Medical Council of the State of Hesse, Frankfurt, Germany.